🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

MASked-unconTrolled hypERtension Management Based on Office BP or on Out-of-office (Ambulatory) BP Measurement

RecruitingNAAges 35 Years - 80 YearsAllIstituto Auxologico Italiano
NCT02804074 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

MASTER study is a 4-year prospective, randomized, open-label, blinded-endpoint study (PROBE) comparing 2 management strategies 1) office BP as a guide to treatment, or 2) 24-hour ABP as a guide to treatment. Study objectives are to investigate whether a management strategy based on out-of-office BP (Ambulatory BP monitoring) versus a management strategy based on office BP measurements is associated with differences in outcome, including cardiovascular and renal intermediate end points at one year; cardiovascular events at 4 years and changes in a number of blood pressure-related variables throughout the study. Patients will be followed-up during the first year focusing on changes in left ventricular mass index (LVMI, co-primary endpoint) and Urinary albumin excretion (UAE, albumin/creatinine ratio, co-primary end-point), and during the whole 48 month period for both changes in LVMI and U

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Male and female subjects * Age 35-80 years * Masked uncontrolled (in treatment) hypertension: office BP \<140/90 mmHg, and one or more of the following situations: * Ambulatory daytime BP \>135/85 mmHg * Ambulatory night-time ABP \> 120/70 mmHg * Ambulatory 24h ABP \>130/80 mmHg * eGFR ≥45 mL/min/1.73 m2 (CKD-EPI creatinine equation 2009) Exclusion Criteria: * eGFR \<45 mL/min/1.73 m2 (CKD-EPI creatinine equation 2009), and in particular severe chronic renal failure defined as serum creatinine \> 250 umol/l; * Patients in unstable clinical conditions; * Known secondary hypertension; * Orthostatic hypotension (SBP fall \> 20 mmHg on standing); * Dementia (clinical diagnosis); * Hepatic disease as determined by either AST or ALT values \> 2 times the upper limit of normal * History of gastrointestinal surgery or disorders which could interfere with drug absorption * Known allergy or contraindications to one of the drugs to be administered in the study * History of malignancy including leukaemia and lymphoma (but not basal cell skin cancer) within the last 5 years * History of clinically significant autoimmune disorders such as systemic lupus erythematosus. * History of drug or alcohol abuse within the last 5 years * History of non-compliance to medical regimens and/or patients who are considered potentially unreliable * Inability or unwillingness to give free informed consent * Pregnancy or planned pregnancy during study period.
💊

What it tests

  • Optimization of antihypertensive treatment based on office BP
  • Optimization of antihypertensive treatment based on 24-hour ABPM
📍

Where

2 sites
Istituto Auxologico Italiano
Milan, Italy
Fundacion Venezolana de Hipertension Arterial/Instituto de Enfermedades Cardiovasculares de LUZ
Maracaibo, Venezuela
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy